{"analyses":[{"ciLowerLimit":"0.719","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.128","groupDescription":"A sample size of 684 analyzable patients provides 80% power to detect a relative reduction of 25% in the rate of death in the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group, assuming a 2-year rate of overall survival of 45% in the standard-fractionation radiotherapy group, with the use of a one-sided log-rank test at the 0.05 significance level.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.180","paramType":"Hazard Ratio (HR)","paramValue":"0.90","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.3","upperLimit":"69.2","value":"64.3"},{"groupId":"OG001","lowerLimit":"65.6","upperLimit":"75.1","value":"70.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death (failure) or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The full distribution is the outcome of interest, and the protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Three-year estimates are provided as a summary of the distributions. Analysis was planned to occur after 309 deaths had been reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.","id":"OG000","title":"Standard Fractionation RT + Cisplatin"},{"description":"Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.","id":"OG001","title":"Accelerated Fractionation RT + Cisplatin"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Follow-up schedule from end of treatment: 6-8 weeks, every 3 mo. for 2 yr., then every 6 mo. for 3 yr., then yearly. Maximum follow-up at time of analysis was 6.5 years. Three-year rates are reported here.","title":"Overall Survival (Percentage of Participants Alive)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}